Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study

Observational studies of up to 12 months duration showed that glatiramer acetate (GA) treatment of relapsing-remitting multiple sclerosis may result in decreased fatigue and improves health-related quality of life (HRQoL), with no changes in disability or mood. We investigated whether in the second...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongen, Peter Joseph, Lehnick, Dirk, Koeman, Jan, Frequin, Stephan, Heersema, Dorothea, Kornips, Bert, Schyns-Soeterboek, Angelique, Visser, Leo H., Schiphof, Paul, Valkenburg, Anton, Hiel, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119257/
https://www.ncbi.nlm.nih.gov/pubmed/24792727
http://dx.doi.org/10.1007/s00415-014-7363-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119257/
https://www.ncbi.nlm.nih.gov/pubmed/24792727
http://dx.doi.org/10.1007/s00415-014-7363-2

Ejemplares similares